Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
Journal Article
|Research
2024-12-10 • Clinical Infectious Diseases
2024-12-10 • Clinical Infectious Diseases
BACKGROUND
The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...
Journal Article
|Research
2022-11-10 • PLOS One
2022-11-10 • PLOS One
BACKGROUND
Journal Article
|Research
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, so...
Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, so...